VIM and lung cancer: In an in vivo model of salt‐sensitive hypertension, it should be noted that MCC950 attenuated the expression of vimentin and several inflammatory/injury markers in the kidney.[50] Mechanistically, MCC950 can also impair the combination of NLRP11 and vimentin and inhibit the acetylation of vimentin mediated by KAT7 at K104, suggesting that MCC950 has potential antitumor value in patients with vimentin‐K104Ac‐positive lung cancer.